In conclusion, KBP-089 acts complementary with the GLP-1 analogue, liraglutide, on food consumption, weight loss and glucose tolerance, indicating the potential for an add-on therapy causing additional improvement in metabolic profile. This evidence concerns the gene GLP1R and glucose measurement.